{"id":40048,"date":"2024-02-01T14:18:02","date_gmt":"2024-02-01T13:18:02","guid":{"rendered":"https:\/\/www.satt.fr\/?p=40048"},"modified":"2024-02-01T14:24:19","modified_gmt":"2024-02-01T13:24:19","slug":"proterna","status":"publish","type":"post","link":"https:\/\/www.satt.fr\/en\/proterna\/","title":{"rendered":"La Success Story du mois : ProteRNA"},"content":{"rendered":"
\n
\n\t

#Vers l\u2019acc\u00e8s g\u00e9n\u00e9ralis\u00e9 des vaccins \u00e0 ARN messager (ARNm) !<\/span><\/p>\n<\/div>\n<\/div><\/div><\/div><\/div>

\"\"<\/div><\/div>
\n
\n\t

Un accord de licence entre la SATT Aquitaine<\/a> et Nexbiome Therapeutics<\/a> a \u00e9t\u00e9 \u00e9tabli pour exploiter une technologie novatrice \u00e9labor\u00e9e par une \u00e9quipe du laboratoire de recherche I2M (universit\u00e9 de Bordeaux, CNRS, Bordeaux INP, Arts et M\u00e9tiers) et une \u00e9quipe de l\u2019UTCBS (Universit\u00e9 Paris Cit\u00e9, CNRS, Inserm).<\/strong><\/p>\n

Cette innovation repose sur une m\u00e9thode unique de stabilisation de l'ARN, pr\u00e9sent\u00e9 sous forme de comprim\u00e9 pouvant \u00eatre conserv\u00e9 \u00e0 temp\u00e9rature ambiante, facilitant une administration par voie orale.<\/strong><\/p>\n<\/div>\n<\/div><\/div><\/div><\/div>

\n
\n\t

Le projet ProteRNA : proposer des vaccins sous forme de comprim\u00e9s<\/h2>\n<\/div>\n<\/div><\/div><\/div><\/div>
\n
\n\t

Le projet ProteRNA, est issu de l\u2019association des comp\u00e9tences en g\u00e9nie des proc\u00e9d\u00e9s pharmaceutiques de l\u2019\u00e9quipe du professeur Pierre Tchoreloff, de l\u2019Institut de m\u00e9canique et d'ing\u00e9nierie (I2M, universit\u00e9 de Bordeaux, CNRS, Bordeaux INP, Arts et M\u00e9tiers), combin\u00e9es \u00e0 celles en vectorisation des acides nucl\u00e9iques de l\u2019\u00e9quipe de Virginie Escriou, directrice de recherche \u00e0 l\u2019Unit\u00e9 des Technologies Chimiques et Biologiques pour la Sant\u00e9 (Universit\u00e9 Paris Cit\u00e9, CNRS, Inserm).<\/p>\n

L\u2019invention consiste dans la fabrication d'un comprim\u00e9 muco-adh\u00e9sif renfermant un vecteur de type acide nucl\u00e9ique (ARN interf\u00e9rents, ARNm) capable de d\u00e9clencher une r\u00e9ponse immunitaire apr\u00e8s administration dans la cavit\u00e9 buccale. Malgr\u00e9 les d\u00e9fis technologiques associ\u00e9s aux proc\u00e9d\u00e9s de mise en forme tels que la lyophilisation et la compression, cette forme s\u00e8che de comprim\u00e9 offre plusieurs avantages :<\/p>\n

    \n
  • l\u2019administration par voie orale,<\/li>\n
  • une stabilit\u00e9 significative de la forme pharmaceutique<\/li>\n
  • un d\u00e9ploiement simplifi\u00e9 de la vaccination \u00e0 grande \u00e9chelle<\/li>\n
  • un confort accru pour le patient<\/li>\n
  • une logistique facilit\u00e9e par la gal\u00e9nique du traitement sous forme de comprim\u00e9s.<\/li>\n<\/ul>\n<\/div>\n<\/div><\/div><\/div><\/div>
    \n
    \n\t

    Un investissement de 166 000 \u20ac de par la SATT Aquitaine et le CNRS !<\/h2>\n<\/div>\n<\/div><\/div><\/div><\/div>
    \n
    \n\t

    En 2017, le projet ProteRNA a fait l\u2019objet d\u2019un d\u00e9p\u00f4t de brevet par la SATT Aquitaine et d\u2019un financement de pr\u00e9-maturation de pr\u00e8s de 72 000\u20ac par le CNRS pour d\u00e9velopper la solution sur l\u2019axe des ARN interf\u00e9rents : de courtes mol\u00e9cules d'ARN r\u00e9gulatrices qui peuvent r\u00e9duire au silence des g\u00e8nes se liant sp\u00e9cifiquement avec l'ARN messager cible, conduisant \u00e0 la d\u00e9gradation de celui-ci et de ce fait, \u00e0 l'inhibition de l'expression de la prot\u00e9ine correspondante.<\/p>\n

    En 2021, la pand\u00e9mie de covid-19 a mis en lumi\u00e8re la technologie des vaccins \u00e0 ARN messager (ARNm), mais souligne \u00e9galement les d\u00e9fis li\u00e9s \u00e0 leur d\u00e9ploiement et au stockage dans des cong\u00e9lateurs d\u00e9di\u00e9s. S\u2019appuyant sur les travaux des chercheurs, la SATT Aquitaine a investi 94 300\u20ac en maturation pour amener la technologie \u00e0 une preuve de concept sp\u00e9cifique aux vaccins \u00e0 ARNm. Cette \u00e9tape a \u00e9t\u00e9 r\u00e9alis\u00e9e en collaboration avec la soci\u00e9t\u00e9 Nexbiome Therapeutics pour concevoir le cahier des charges et d\u00e9finir le positionnement th\u00e9rapeutique le mieux adapt\u00e9.<\/p>\n<\/div>\n<\/div><\/div><\/div><\/div>

    \n
    \n\t

    Nexbiome Therapeutics est un incubateur priv\u00e9 de projets de recherche. Elle source des concepts acad\u00e9miques dans le but de cr\u00e9er des biotechs \u00e0 ambition mondiale, sp\u00e9cialis\u00e9es dans les projets de microbiote th\u00e9rapeutique en sant\u00e9 humaine.<\/p>\n

    Les r\u00e9sultats concluants de la maturation ont ensuite d\u00e9cid\u00e9 Nexbiome Therapeutics d'acqu\u00e9rir la licence d'exploitation de la technologie ProteRNA. Cette licence permet dans un premier temps \u00e0 Nexbiome de poursuivre la collaboration avec l'\u00e9quipe de recherche, avec l'objectif de mettre sur le march\u00e9 des vaccins ARNm sous forme de comprim\u00e9s dans les ann\u00e9es \u00e0 venir.<\/p>\n<\/div>\n<\/div><\/div><\/div><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"

    #Vers l\u2019acc\u00e8s g\u00e9n\u00e9ralis\u00e9 des vaccins \u00e0 ARN messager (ARNm) ! Un accord de licence entre la SATT Aquitaine et Nexbiome Therapeutics a \u00e9t\u00e9 \u00e9tabli pour exploiter une technologie novatrice \u00e9labor\u00e9e par une \u00e9quipe du laboratoire de recherche I2M (universit\u00e9 de Bordeaux, CNRS, Bordeaux INP, Arts et M\u00e9tiers) et une \u00e9quipe de l\u2019UTCBS (Universit\u00e9 Paris Cit\u00e9, […]<\/p>\n","protected":false},"author":2,"featured_media":40061,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[536],"tags":[],"class_list":["post-40048","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-actualite"],"acf":[],"yoast_head":"\nLa Success Story du mois : ProteRNA - R\u00e9seau SATT<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.satt.fr\/proterna\/\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.satt.fr\/proterna\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.satt.fr\/proterna\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/www.satt.fr\/en\/#\/schema\/person\/6f20a7d0bc03146f6e34a9f08d941fec\"},\"headline\":\"La Success Story du mois : ProteRNA\",\"datePublished\":\"2024-02-01T13:18:02+00:00\",\"dateModified\":\"2024-02-01T13:24:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.satt.fr\/proterna\/\"},\"wordCount\":612,\"image\":{\"@id\":\"https:\/\/www.satt.fr\/proterna\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.satt.fr\/wp-content\/uploads\/2024\/02\/la-successstory-du-mois-3-1.png\",\"articleSection\":[\"Actualit\u00e9\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.satt.fr\/proterna\/\",\"url\":\"https:\/\/www.satt.fr\/proterna\/\",\"name\":\"La Success Story du mois : ProteRNA - R\u00e9seau SATT\",\"isPartOf\":{\"@id\":\"https:\/\/www.satt.fr\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.satt.fr\/proterna\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.satt.fr\/proterna\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.satt.fr\/wp-content\/uploads\/2024\/02\/la-successstory-du-mois-3-1.png\",\"datePublished\":\"2024-02-01T13:18:02+00:00\",\"dateModified\":\"2024-02-01T13:24:19+00:00\",\"author\":{\"@id\":\"https:\/\/www.satt.fr\/en\/#\/schema\/person\/6f20a7d0bc03146f6e34a9f08d941fec\"},\"breadcrumb\":{\"@id\":\"https:\/\/www.satt.fr\/proterna\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.satt.fr\/proterna\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.satt.fr\/proterna\/#primaryimage\",\"url\":\"https:\/\/www.satt.fr\/wp-content\/uploads\/2024\/02\/la-successstory-du-mois-3-1.png\",\"contentUrl\":\"https:\/\/www.satt.fr\/wp-content\/uploads\/2024\/02\/la-successstory-du-mois-3-1.png\",\"width\":1434,\"height\":800},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.satt.fr\/proterna\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/www.satt.fr\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"La Success Story du mois : ProteRNA\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.satt.fr\/en\/#website\",\"url\":\"https:\/\/www.satt.fr\/en\/\",\"name\":\"R\u00e9seau SATT\",\"description\":\"Les Soci\u00e9t\u00e9s d'Acc\u00e9l\u00e9ration du Transfert de Technologies\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.satt.fr\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.satt.fr\/en\/#\/schema\/person\/6f20a7d0bc03146f6e34a9f08d941fec\",\"name\":\"admin\",\"url\":\"https:\/\/www.satt.fr\/en\/author\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"La Success Story du mois : ProteRNA - R\u00e9seau SATT","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.satt.fr\/proterna\/","twitter_misc":{"Written by":"admin","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.satt.fr\/proterna\/#article","isPartOf":{"@id":"https:\/\/www.satt.fr\/proterna\/"},"author":{"name":"admin","@id":"https:\/\/www.satt.fr\/en\/#\/schema\/person\/6f20a7d0bc03146f6e34a9f08d941fec"},"headline":"La Success Story du mois : ProteRNA","datePublished":"2024-02-01T13:18:02+00:00","dateModified":"2024-02-01T13:24:19+00:00","mainEntityOfPage":{"@id":"https:\/\/www.satt.fr\/proterna\/"},"wordCount":612,"image":{"@id":"https:\/\/www.satt.fr\/proterna\/#primaryimage"},"thumbnailUrl":"https:\/\/www.satt.fr\/wp-content\/uploads\/2024\/02\/la-successstory-du-mois-3-1.png","articleSection":["Actualit\u00e9"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.satt.fr\/proterna\/","url":"https:\/\/www.satt.fr\/proterna\/","name":"La Success Story du mois : ProteRNA - R\u00e9seau SATT","isPartOf":{"@id":"https:\/\/www.satt.fr\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.satt.fr\/proterna\/#primaryimage"},"image":{"@id":"https:\/\/www.satt.fr\/proterna\/#primaryimage"},"thumbnailUrl":"https:\/\/www.satt.fr\/wp-content\/uploads\/2024\/02\/la-successstory-du-mois-3-1.png","datePublished":"2024-02-01T13:18:02+00:00","dateModified":"2024-02-01T13:24:19+00:00","author":{"@id":"https:\/\/www.satt.fr\/en\/#\/schema\/person\/6f20a7d0bc03146f6e34a9f08d941fec"},"breadcrumb":{"@id":"https:\/\/www.satt.fr\/proterna\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.satt.fr\/proterna\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.satt.fr\/proterna\/#primaryimage","url":"https:\/\/www.satt.fr\/wp-content\/uploads\/2024\/02\/la-successstory-du-mois-3-1.png","contentUrl":"https:\/\/www.satt.fr\/wp-content\/uploads\/2024\/02\/la-successstory-du-mois-3-1.png","width":1434,"height":800},{"@type":"BreadcrumbList","@id":"https:\/\/www.satt.fr\/proterna\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.satt.fr\/en\/"},{"@type":"ListItem","position":2,"name":"La Success Story du mois : ProteRNA"}]},{"@type":"WebSite","@id":"https:\/\/www.satt.fr\/en\/#website","url":"https:\/\/www.satt.fr\/en\/","name":"R\u00e9seau SATT","description":"Les Soci\u00e9t\u00e9s d'Acc\u00e9l\u00e9ration du Transfert de Technologies","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.satt.fr\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.satt.fr\/en\/#\/schema\/person\/6f20a7d0bc03146f6e34a9f08d941fec","name":"admin","url":"https:\/\/www.satt.fr\/en\/author\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/posts\/40048","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/comments?post=40048"}],"version-history":[{"count":5,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/posts\/40048\/revisions"}],"predecessor-version":[{"id":40058,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/posts\/40048\/revisions\/40058"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/media\/40061"}],"wp:attachment":[{"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/media?parent=40048"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/categories?post=40048"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/tags?post=40048"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}